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Background: Elevated serum YKL-40 levels have been observed in various cancers. We evaluated the diagnostic
performance of serum YKL-40 alone or in combination with the CEA, CYFRA21-1 and SCCA tumor markers for
patients with esophageal squamous cell carcinoma (ESCC).
Methods: YKL-40 was detected in ESCC cell lines and tissues by real-time RT-PCR, Western blotting and ELISA.
YKL-40 protein expression was determined in 20 ESCC tumor tissues using immunohistochemistry. Serum YKL-40
was measured by ELISA in 126 healthy donors, 59 patients with benign esophageal diseases and 150 patients with
ESCC. Serum CEA, CYFRA21-1 and SCCA were determined by electrochemiluminescence.
Results: YKL-40 mRNA and protein were observed in ESCC cancer cell lines, tissues and cell culture media,
respectively. YKL-40 expression was observed in 17 of 20 ESCC samples (85%). Serum YKL-40 concentration was
significantly elevated in patients with ESCC (Range: 6.95-502.10 ng/ml) compared with patients with benign diseases
(Range: 1.21-429.30 ng/ml; P = 0.038) and healthy controls (Range: 2.56-132.26 ng/ml; P < 0.001). ROC curves
demonstrated that serum YKL-40 has a sensitivity of 72.70%, a specificity of 84.13% and an AUC of 0.874 for the
diagnosis of ESCC, which was superior to CEA (Sen: 8.00%; Spe: 96.80%, AUC = 0.652), CYFRA21-1 (Sen: 40.00%; Spe:
92.06%, AUC = 0.746) and SCCA (Sen: 32.67%; Spe: 94.44%, AUC = 0.789). The YKL-40 and SCCA combination was
better for diagnosing ESCC (Sen: 82.00%, Spe: 79.37%, PPV: 82.55 and NPV: 78.74; AUC = 0.917) than the YKL-40 and
CEA combination (Sen: 74.00%, Spe: 83.20%, PPV: 84.09 and NPV: 72.73; AUC = 0.877), the YKL-40 and CYFRA21-1
combination (Sen: 82.00%, Spe: 77.78%, PPV: 81.46% and NPV: 78.40%; AUC = 0.897) or the CEA, CYFRA21-1 and
SCCA combination (Sen: 56.67%, Spe: 84.80%, PPV: 81.73 and NPV: 61.99; AUC = 0.831). Associations between serum
YKL-40 levels and the clinic characteristics of ESCC were not significant, with the exception of age (p = 0.001).
Conclusions: ESCC tumor cells and tissues express YKL-40. Serum YKL-40 may be a potential biomarker for ESCC.
Serum YKL-40 in combination with SCCA significantly increases the sensitivity of detecting ESCC.
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<60 81 71.56(6.95-340.70) 0.001
≥60 69 122.36(21.32-502.05) 0.001
Gender
Male 113 93.12(11.56-430.83) 0.784
Female 37 111.60(6.95-502.05) 0.784
pT status
pT1 5 93.12(21.32-264.66) 0.975
pT2 21 104.27(30.26-430.83) 0.975
pT3 65 91.55(6.95-421.34) 0.975
pT4 45 101.50(14.64-351.66) 0.975
pN status
pN0 57 97.27(6.95-430.83) 0.617
pN1 77 97.03(13.32-421.34) 0.617
pM status
pM0 107 93.24(6.95-430.83) 0.198
pM1 32 108.82(14.64-419.22) 0.198
pTNM status
Stage I 7 93.12(42.26-264.66) 0.604
Stage II 40 97.27(6.95-430.83) 0.604
Stage III 58 92.40(13.32-421.34) 0.604
Stage IV 32 108.82(14.64-419.22) 0.604
Tumor grade
Grade 1 24 108.39(24.95-234.89) 0.579
Grade 2 57 94.21(11.56-376.09) 0.579
Grade 3 41 71.02(6.95-419.22) 0.579
aKruskal-Wallis test.
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Esophageal squamous cell carcinoma (ESCC) is typically
diagnosed at a late state and therefore has a very high
mortality rate. It is the sixth leading cause of cancer
mortalities worldwide [1]. The overall 5-year survival
rate for patients treated with surgery alone is less than
20%, with a median survival of 13 to 17 months [2-5].
Currently, traditional tumor markers, such as CEA,
CYFRA21-1 and SCCA, are used to diagnose and evalu-
ate ESCC progression. However, these tumor markers
exhibit a low sensitivity in detecting ESCC. Kawaguchi
H demonstrated that the diagnostic sensitivity of CEA
was only 17.0% in ESCC [6]. Mealy K reported that the
individual sensitivities of CEA and SCCA for the diagno-
sis of ESCC were about 28% and 32%, respectively [7].
Yamamoto K study demonstrated that the sensitivity of
CYFRA 21-1 was only 47.9%, although the specificity
was 100% [8]. Likewisely, our previous study reported
that CEA and CYFRA21-1 exhibited sensitivities of
13.4% and 32.1% for the detection of ESCC, respectively
[9]. These results indicate that the sensitivity of the trad-
itional ESCC tumor markers is too low to diagnose
esophageal cancer diagnosis. Therefore, there is an urgent
need to identify tumor markers to improve the sensitivity
of ESCC detection.
YKL-40, a secreted glycoprotein, belongs to a group of
mammalian proteins with an amino acid sequence that
is similar to the 18-glycosyl hydrolase group of bacterial
chitinases [10]. It is secreted by various human cells, such
as synovial, cartilage, endothelial, neutrophil and macro-
phage cells [11]. YKL-40 is involved in angiogenesis,
growth, proliferation, differentiation, and remodeling
processes [12]. Serum YKL-40 levels are elevated in
pathological conditions, including inflammation and
cancer [13,14]. Recently, YKL-40 was reported to be
highly expressed in several types of cancers, including
ovarian cancer [15], breast cancer [16], lung cancer [17],
hepatocellular carcinoma [18], and glioblastoma [19]. In
addition, serum YKL-40 has been suggested as a poten-
tial biomarker for the diagnosis and monitoring of these
cancers [20-24].
The diagnostic value of serum YKL-40 in patients with
ESCC remains unknown. The goal of our present study
is to investigate the levels of YKL-40 expression in ESCC
tumor cells and to evaluate the diagnostic performance
of serum YKL-40 in ESCC diagnosis compared with the




The immortalized esophageal epithelial cell line NE-3,
induced by human papillomavirus type 16 E6/E7, was
obtained from Dr. Jin (the University of Hong Kong,P.R. China) and was cultured in Keratinocyte-SFM
(Invitrogen, Carlsbad, CA) media [25,26]. The ESCC
cell lines Eca-109, Kyse30, Kyse140, Kyse180, Kyse510
and Kyse520 (Chinese Academy of Sciences, Shanghai,
China) were grown in RPMI 1640 (Invitrogen, USA)
supplemented with 10% fetal bovine serum [26].
Serum and tissue specimen
Serum from 150 ESCC patients (ages 30-96 years, median
58 years) was collected at the time of diagnosis before
tumor resection at the Cancer Center of Sun Yat-Sen
University from 2002 to 2005. The patient characteris-
tics are described in Table 1. The absence of disease
such as COPD and second primary carcinomas was
assessed by clinical history, physical examination, rou-
tine laboratory tests (including liver and renal function
tests), and colonoscopy. Serum from 126 healthy donors
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74 males and 52 females) were collected from the physical
examination department at the Cancer Center of Sun
Yat-Sen University. Serum of 59 patients (ages 21-80
years, median = 55 years, 35 males and 24 females)
with benign esophageal disease (40 cases of reflux
esophagitis, 6 cases of acute suppurative esophagitis
and 13 cases of esophageal hiatal hernia) were col-
lected at the first affiliated hospital of Sun Yat-sen
University. Venous blood (3-5 ml) was obtained at the
time of diagnosis before treatment, clotted at room
temperature, centrifuged at 3000 r/min for 10 min and
stored at -80°C until use.
A total of 20 formalin-fixed and paraffin-embedded
ESCC tumor specimens for immunochemistry were ob-
tained at the Sun Yat-sen University Cancer Center from
November of 2012 to December of 2013. Six pairs Real-
time RT-PCR and Western-blotting tissue samples were
obtained from 2011 to 2013. The corresponding normal
esophageal tissue specimens (n = 20) were taken from
areas a standard distance (8 cm) from the corresponding
resected tumors. All these ESCC and carcinoma-adjacent
tissue samples were collected immediately after surgical
resection and confirmed by pathological review.
Prior to use of these serum and tissues, informed consent
was obtained from each of the participants. All patients
provided written informed consent. This experiment was
approved by the Institute Research Ethics Committee of
the Cancer Center of Sun Yat-Sen University, Guangzhou,
China.
Real-time RT-PCR
Total RNA was extracted from cell lines and frozen
ESCC tissues using the Trizol reagent (Invitrogen, USA)
according to the manufacture’s instruction.
Reverse transcription of total RNA (2 μg) was done
using SuperScript II reverse transcriptase. The quanti-
fication of target and reference (GAPDH) genes was
performed in triplicate on a LightCycler® 480 II (Roche,
Applied Science) using a SYBR green-based assay
(BioRad, USA). The primers used in the real-time RT-
PCR reaction were as follows: YKL-40 forward 5′- GAG
GATGGAACTTTGGGTCTC-3′ and reverse 5′- TCAT




Western blot analysis was performed via standard proto-
cols with antibodies to YKL-40 and α-tublin (Abcam, UK).
Immunohistochemistry
Formalin-fixed, paraffin-embedded ESCC sections were
incubated with a rabbit polyclonal anti-YKL-40 antibody(1:100, Bioss, China) overnight at 4°C. After washing in
PBST, the tissue sections were treated with a horseradish
peroxidase-conjugated anti-rabbit secondary antibody
(1:1000, Zymed). The tissue sections were then developed
with 3-diaminobenzidine tetrahydrochloride for 10 sec-
onds, followed by counterstaining with 10% Mayer’s
hematoxylin. The degree of immunostaining was reviewed
by two independent observers.
ELISA
Serum YKL-40 levels were determined by double-antibody
sandwich ELISA according to the manufacturer’s instruc-
tions (R&D systems, USA). Briefly, 96-well microplates
were coated with 100 μl/well of the capture antibody (rat
anti-human YKL-40, 2.0 μg/ml) overnight at 4 C. After
blocking with 3% BSA, 100 μl of the test samples (1:100
diluted in 1% BSA) was added and incubated for 2 h at
room temperature. Subsequently, 100 μl/well of the de-
tection antibody (biotinylated goat anti-human YKL-40,
200 ng/ml) was added and incubated for 2 h at room
temperature. Next, 100 μl/well of Streptavidin-HRP
(1:200) was added and incubated for 20 min at room
temperature. Finally, the substrate (tetramethylbenzi-
dine) solution was added, and the reaction was stopped
with 2 N H2SO4 and read at an OD of 450 nm. Each test
included a standard control (CV = 12%).
CEA, CYFRA21-1 and SCCA assay
The concentrations of CEA and CYFRA21-1 in the serum
were assessed using electrochemiluminescence immuno-
assay (ECLIA) kits (CEA, lot: 172356; CYFRA21-1, lot:
169393; Roche, German) on a Roche E170 fully automatic
electrochemistry luminescence immunity analyzer (Roche,
German). The levels of SCCA in the serum were de-
tected using an ARCHITECT I2000SR immune analyze
system (Abbott, America) (SCCA, lot: 34111LP68; Abbott,
America). Each test included a standard control (CV < 5%).
Statistical analysis
Statistical analyses were performed with the SPSS 16.0
(SPSS Inc.) The relationships between the expression of
YKL-40 protein and the clinicopathologic features were
analyzed by the Mann-Whitney U test. The comparisons
of YKL-40 concentration among different groups were
assessed using the Kruskal-Wallis test. The efficacy of
YKL-40 was evaluated by the area under receiver oper-
ating characteristic (ROC) curve (AUC). The cut-off
value for YKL-40 was defined as the value with the
maximization of the Yuden index. Furthermore, sensi-
tivity (Sen), specificity (Spe), positive predictive value
(PPV) and negative predictive value (NPV) were used to
compare the efficiency of diagnosis among YKL-40,
CEA, CYFRA21-1 and SCCA. All statistical tests were
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Results
Expression of YKL-40 in esophageal carcinoma cell lines
and tumor tissues
To investigate the expression of YKL-40 in ESCC, the
YKL-40 mRNA and protein levels were detected by
real-time RT-PCR and Western Blotting, respectively, inFigure 1 Expression of YKL-40 mRNA or protein in ESCC cell lines, tis
immortalized esophageal epithelial cell line (NE-3) and esophageal carcinom
respectively (A, B) and in six pairs of matched ESCC and noncancerous tiss
respectively. Error bars represent standard deviations (SD) calculated from t
by ELISA (C). Location of YKL-40 was determined by immunohistochemistr
YKL-40 (F a-b, 200 × and 400×). The ESCC tissues showed low (F c-d), medseveral esophageal carcinoma cell lines (Eca-109, Kyse180,
Kyse510, Kyse30, Kyse140 and Kyse520) and the im-
mortalized esophageal epithelial cell line NE-3. As
shown in Figure 1A and B, higher YKL-40 mRNA and
protein levels were observed in all tumor cell lines com-
pared with the immortalized cell line NE-3. Next, we per-
formed a double-antibody sandwich ELISA to determine
the protein expression of YKL-40 in the media of the cell
lines. The levels of YKL-40 protein observed in the mediasues and location in tissue. Expression of mRNA and protein in
a cell lines was analyzed by real-time PCR and Western Blotting,
ues (D, E). Expression level was normalized by GAPDH and α-tublin,
hree parallel experiments. Protein level in supernatant was measured
y (F). The normal esophageal epithelial tissue showed no expression of
ium (F e-f) and high (F g-h) expression of YKL-40 (200× and 400×).
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but were still higher than that of NE-3 (Figure 1C). Thus,
consistent with the results of the mRNA analysis, YKL-40
protein expression was up-regulated in the ESCC cell
lines. Furthermore, comparative analysis of YKL-40 ex-
pression was conducted on six pairs of matched ESCC tis-
sue and adjacent noncancerous tissue. The expression of
YKL-40 mRNA in the six ESCC samples was much higher
than the paired adjacent noncancerous tissue (Figure 1D).
Similarly, the expression level of YKL-40 protein was also
increased in ESCCs compared with that in the adjacent
nonmalignant esophageal tissues (Figure 1E).
To further investigate the exact expression state of
YKL-40 in vivo, YKL-40 protein expression was deter-
mined by immunohistochemistry. YKL-40 protein was
detected in 17 of 20 ESCC samples (85%) but not in the
normal esophageal epithelium (Figure 1F). YKL-40 was
mainly located in the cytoplasm of tumor cells, as well
as in the tumor stroma cells. The expression levels of
YKL-40 in tumor cells was observed at various levels:
low (Figure 1F c-d), medium (Figure 1F e-f ) and high
(Figure 1F g-h). The high expression of YKL-40 was also
observed in mesenchymal cells surrounding carcinoma
(Figure 1F g-h).
Serum YKL-40 levels in ESCC and the association between
serum YKL-40 and clinicopathological characteristics
Figure 2 presents the serum levels of YKL-40 in the pa-
tients with ESCC (n = 150), patients with benign esopha-
geal diseases (n = 59), healthy controls (n = 126) and
patients with early-stage ESCC (n = 47, 7 cases of stage I,
40 cases of stage II). The mean YKL-40 level was
97.27 ng/ml (range, 6.95-502.10) in patients with ESCC,
57.97 ng/ml (range, 1.21-429.30) in patients with benign
esophageal diseases, 23.89 ng/ml (range, 2.56-132.26) inFigure 2 YKL-40 concentration in serum in the test cohort. Left side, th
controls and early-stage ESCC patients are plotted as a distribution. P value
in different groups.healthy controls and 97.27 ng/ml (range, 6.95-430.80) in
early stage ESCC. The serum levels of YKL-40 in pa-
tients with ESCC were significantly higher than those of
healthy control subjects (p < 0.001) and those of patients
with benign disease (p = 0.038), and the serum levels of
YKL-40 of the early-stage ESCC patients were signifi-
cantly higher than healthy control subjects (p < 0.001) but
similar to benign disease patients (p = 0.2126) (Figure 2).
The associations between the median serum YKL-40
levels and the clinicopathological parameters are pre-
sented in Table 1. Serum YKL-40 was not significantly
correlated with gender, T classification, N classification,
metastasis, clinical stage or tumor grade. However, there
was a significant association between the level of serum
YKL-40 and age (p = 0.001). The level of serum YKL-40
was higher in elder patients (≥60) than in patients below
the age of 60.
Diagnostic values of individual serum YKL-40, CEA,
CYFRA21-1 and SCCA levels or combinations in the
detection of ESCC
The ROC curve was plotted to identify a cut-off value that
could distinguish 150 ESCC patients from 126 healthy
controls. As shown in Figure 3, the AUC of YKL-40 was
0.874 (95% CI: 0.792–0.885), with an optimal cut-off value
58.0 ng/ml, whereas the AUCs of CEA, CYFRA21-1 and
SCCA were 0.652 (95% CI: 0.593–0.708), 0.746 (95% CI:
0.691–0.797) and 0.789(95% CI: 0.736–0.842), respectively.
The cut-off values that we applied for CEA, CYFRA21-1
and SCCA were 5.0 ng/ml, 3.3 ng/ml and 1.5 ng/ml, re-
spectively, according to the manufacturer’s protocols. As
shown in Table 2, the sensitivity of YKL-40 was 72.70%,
which is significantly higher than that for CEA (8.00%),
CYFRA21-1 (40.00%) and SCCA (32.67%), whereas the
specificity of serum YKL-40 was slightly lower. Moreover,e serum YKL-40 in ESCC patients, benign disease patients, healthy
was calculated using Kruskal-Wallis test. Right side, YKL-40 serum levels
Figure 3 Diagnostic outcomes for serum YKL-40, CEA, CYFRA21-1 or SCCA in the diagnosis of ESCC. A. ROC curves of the serum YKL-40
levels of 150 ESCC patients and 126 controls. The estimated area under the ROC curve was observed as AUC = 0.874. B. ROC curves for the
diagnostic strength to identify ESCC using YKL-40, CEA, CYFRA21-1 or SCCA (CEA: AUC = 0.652; CYFRA21-1 = 0.746; SCCA = 0.789).
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CEA, CYFRA21-1 and SCCA (72.11% vs. 46.72% vs.
56.31% vs. 54.09%) without an obvious reduction in
the PPV.
To further improve diagnostic accuracy, we used par-
allel combinations to establish models with the above-
mentioned seromarkers. That is, the sample would be
defined as positive for ESCC if any of the markers in
the combination was above the cut-off value. Table 2
demonstrates that the sensitivity of the combination of
YKL-40 and SCCA (82.00%) was superior to that of the
combination of CEA, CYFRA21-1 and SCCA (56.67%)
or that of YKL-40 and CEA (74.00%) but was similar to
that of the YKL-40 and CYFRA21-1 combination
(82.00%). The specificity of the combination of YKL-40
and SCCA (79.37%) was slightly lower than the combin-
ation of CEA, CYFRA21-1 and SCCA (84.80%) or the
combination CEA and YKL-40 (83.20%) and slightlyTable 2 Diagnostic values, including sensitivity,
specificity, positive predictive value and negative
predictive value, combining assay seromarkers
Combinations Sensitivity(%) Specificity(%) PPV(%) NPV(%)
YKL-40 72.70 84.13 84.50 72.11
CEA 8.00 96.80 75.00 46.72
CYFRA21-1 40.00 92.06 85.71 56.31
YKL-40 or CEA 74.00 83.20 84.09 72.73
YKL-40 or CYFRA21-1 82.00 77.78 81.46 78.40
CEA or CYFRA21-1 44.00 89.60 69.47 57.14
YKL-40 or CEA or
CYFRA21-1
83.33 76.80 81.17 79.34
Cut-off values: 58.0 ng/ml for YKL-40; 5.0 ng/ml for CEA; 3.3 ng/ml for
CYFRA21-1; 1.5 ng/ml for SCCA.higher than that of the YKL-40 and CYFRA21-1 combin-
ation (77.78%). The combination of YKL-40 and SCCA
(78.74%) exhibited a better NPV than that of the combin-
ation of CEA, CYFRA21-1 and SCCA (61.99%) or the
combination of CEA and YKL-40 (72.73%) or the combin-
ation of YKL-40 and CYFRA21-1 (78.40%). The PPV of
the combination of CEA, CYFRA21-1 and SCCA (81.73%)
was similar to that of the combination of YKL-40 and
CYFRA21-1 (81.46%) or the combination of YKL-40 and
SCCA (82.55%) and was slightly lower than the combin-
ation of CEA and YKL-40 (84.09%). ROC analysis also
demonstrated that the addition of YKL-40 to either tumor
marker significantly increased the AUC of detection of
ESCC (YKL-40 + CEA vs. CEA = 0.877 vs. 0.652; YKL-
40 + CYFRA21-1 vs. CYFRA21-1 = 0.897 vs. 0.746;
YKL-40 + SCCA vs. SCCA = 0.917 vs. 0.789). Moreover,
YKL-40 in combination with SCCA had the highest
classification accuracy among the models with the sero-
markers (CEA +CYFRA21-1 + SCCA: AUC= 0.831; YKL-
40 + CEA: AUC= 0.877 YKL-40 + CYFRA21-1: AUC=
0.897; YKL-40 + SCCA: AUC = 0.917) (Figure 4).
Similarly, Table 3 demonstrates that YKL-40 improved
the sensitivity (70.21%) significantly in detecting early-
stage ESCC compared with the individual tumor markers
(CEA: 10.64%; CYFRA21-1: 40.43%; SCCA: 29.79%), and
the combination of YKL-40 and SCCA was superior to
the other combinations in the efficiency of diagnosing
ESCC.
Discussion
In the present study, we found that YKL-40 protein is
expressed in ESCC cell lines and ESCC tumor tissues.
Serum YKL-40 levels were significantly elevated in pa-
tients with ESCC compared with patients with benign
diseases and healthy controls. Serum YKL-40 in
Figure 4 Diagnostic outcomes for serum YKL-40, CEA, CYFRA21-1 or SCCA combination in the diagnosis of ESCC. A. ROC curves for the
diagnostic strength to identify ESCC using CEA and YKL-40+CEA (CEA: AUC=0.652; YKL-40+CEA: AUC=0.877). B. ROC curves for the diagnostic
strength to identify ESCC using CYFRA21-1 and YKL-40+CYFRA21-1 (CYFRA21-1: AUC=0.746; YKL-40+CYFRA21-1: AUC=0.897). C. ROC curves for
the diagnostic strength to identify ESCC using SCCA and YKL-40+SCCA (SCCA: AUC=0.789; YKL-40+SCCA: AUC=0.917). D. ROC curves for the
diagnostic strength to identify ESCC using YKL-40+CEA, YKL-40+CYFRA21-1, YKL-40+SCCA and CEA+CYFRA21-1+SCCA (YKL-40+CEA: AUC=0.877;
YKL-40+CYFRA21-1: AUC=0.897; YKL-40+SCCA: AUC=0.917; CEA+CYFRA21-1+SCCA: AUC=0.831).
Table 3 Diagnostic values in early stage ESCC combining
assay seromarkers
Combinations Sensitivity(%) Specificity(%) PPV(%) NPV(%)
YKL-40 70.21 84.13 62.26 88.33
CEA 10.64 96.80 55.56 74.23
CYFRA21-1 40.43 92.06 65.52 80.56
YKL-40 or CEA 70.21 83.20 61.11 88.14
YKL-40 or CYFRA21-1 78.72 77.78 56.92 90.74
CEA or CYFRA21-1 46.80 89.60 62.86 81.75
YKL-40 or CEA or
CYFRA21-1
78.72 76.80 56.06 90.57
Cut-off values: 58.0 ng/ml for YKL-40; 5.0 ng/ml for CEA; 3.3 ng/ml for
CYFRA21-1; 1.5 ng/ml for SCCA.
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sitivity of detecting ESCC compared with the traditional
ESCC tumor markers CEA, CYFRA21-1 and SCCA.
A number of studies have reported that YKL-40 is
expressed in tumor cells [27-30]. Due to post-transcriptional
regulation, there are some inconsistencies between mRNA
and protein expression among the esophageal cancer cell
lines. However, in general, YKL-40 was up-regulated in
esophageal cancer cell lines and tumor tissue both at the
transcriptional and translational level compared to the im-
mortalized esophageal epithelial cell line NE-3 and paired
adjacent noncancerous tissue, respectively. Subsequently,
using immunohistochemistry analysis, YKL-40 expression
was observed in 17 (85.0%) of 20 ESCC tumor tissues but
not in neighboring normal esophageal epithelium. These
data suggested that YKL-40, expressed in ESCC tumor
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may be a candidate tumor marker for the detection of
ESCC.
Because YKL-40 is a secreted protein expressed in
tumor cells, it has been investigated as a tumor marker
in many types of cancers. In this study, we tested whether
serum YKL-40 could be used as a tumor marker for
ESCC. Serum YKL-40 levels in the ESCC group were
much higher than in healthy controls. Considering that el-
evated serum YKL-40 levels were observed in patients
with inflammation and the possible influence of chronic
inflammation, we examined YKL-40 expression in a set of
patients with benign esophageal disease and accompany-
ing chronic inflammation (N = 59) to study whether in-
flammation would affect the serum levels of YKL-40. Our
results demonstrated that the serum YKL-40 levels of pa-
tients with benign diseases were significantly higher than
those of healthy controls (p < 0.0001) but significantly
lower than those of the ESCC group (p = 0.038). These
data indicate that patients with benign disease and ele-
vated serum YKL-40 levels exhibit inflammation and that
ESCC patients express higher levels of serum YKL-40 than
do patients with benign diseases. A number of studies
have demonstrated that the development of ESCC is asso-
ciated with chronic inflammation [31-34]. Our previous
study and others determined that the inflammation
markers SAA and CRP are significantly elevated in pa-
tients with ESCC [9]. Both ESCC tumor cells secreting
YKL-40 and inflammation factors increasing YKL-40
expression may account for the higher serum levels of
YKL-40 observed in ESCC patients. Our data show that
YKL-40 is not able to distinguish between patients with
benign disease and early-stage ESCC (p = 0.2126),
possibly due to our small sample size of early-stage
ESCC patients, which was caused by the difficultly
in achieving early diagnosis. In addition, we observed
no correlation between the preoperative serum level
of YKL-40 and patient disease characteristics, with
the exception of age (p = 0.001). There was no sig-
nificant difference in serum YKL-40 levels between
patients with early-stage tumors (I-II) and patients
with advanced-stage tumors (III-IV). These results
indicate that serum YKL-40 can be used for the de-
tection early ESCC as well as for the detection ad-
vanced ESCC.
CEA, CYFRA21-1 and SCCA are the most commonly
investigated tumor markers for the diagnosis of ESCC
[7]. In this study, ROC curve analysis revealed that the
accuracy of serum YKL-40 for the diagnosis of ESCC
was superior that of CEA, CYFRA21-1, and SCCA. In
line with previous studies [6-9], CEA, CYFRA 21-1 and
SCCA exhibited low sensitivity but high specificity for
ESCC detection in our study. However, compared with
CEA, CYFRA 21-1 and SCCA, serum YKL-40 exhibitedhigher sensitivity and slightly lower specificity. The effect
of inflammation factors on the serum levels of YKL-40
may have led to the lower specificity of serum YKL-40
in the diagnosis of ESCC.
CEA, CYFRA 21-1 and SCCA alone exhibit low sen-
sitivity for the diagnosis of ESCC. Researchers have
demonstrated that combinations of tumor markers can
marginally improve diagnostic efficacy compared with
single markers [7,35,36]. In the present study, the
addition of YKL-40 to CEA (74.00%), CYFRA21-1
(82.00%) or SCCA (82.00%) increased the diagnostic
sensitivity compared with CEA (8.00%), CYFRA21-1
(40.00%) or SCCA (32.67%) alone, but the diagnostic
specificity did not significantly decrease. Consistent
with the report of Munck-Wikland et al. [37], our re-
sults demonstrated that reliance on the three trad-
itional tumor markers CEA, CYFRA21-1 and SCCA
for the detection of ESCC is not satisfactory, especially
in light of the poor sensitivity (46.81%). However, the
combination of YKL-40 and SCCA significantly improved
the sensitivity of the detection of ESCC and was superior
to the sensitivity of the three traditional tumor markers
CEA, CYFRA21-1 and SCCA. Moreover, the YKL-40 and
SCCA combination increased the NPV, which can more
accurately differentiate patients from healthy individuals.
ROC analysis also confirmed that YKL-40 in combination
with SCCA was the best model for discriminating between
ESCC cases and controls. Moreover, YKL-40 combined
with SCCA also served as a more sensitive tumor maker
for the detection of patients with early-stage ESCC. Al-
though an analysis of additional patients is needed to ver-
ify and expand the present results, our data indicate that
the addition of YKL-40 to the traditional ESCC tumor
marker SCCA may significantly improve the sensitivity of
the detection of ESCC.Conclusions
In conclusion, our research indicated that YKL-40 is
up-regulated in ESCC tumor and that patients with ESCC
exhibit elevated levels of serum YKL-40. YKL-40 in com-
bination with SCCA significantly improves the sensitivity
of traditional the ESCC tumor markers CEA, CYFRA21-1
and SCCA in the detection of ESCC.Abbreviations
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